866930-72-5

Basic information

• Product Name: tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate
• Synonyms: tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate
• CAS NO: 866930-72-5
• Molecular Weight: 316.198
• Mol File: 866930-72-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate(866930-72-5)
• EPA Substance Registry System: tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate(866930-72-5)

Safety Data

• Hazardous Substances Data: 866930-72-5(Hazardous Substances Data)

Upstream product

• 57260-73-8 N-BOC-1,2-diaminoethane 
• 223463-13-6 2-iodo-5-bromopyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 199522-66-2 N¹-(5-bromopyridin-2-yl)ethane-1,2-diamine 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1401342-10-6 C₂₁H₂₁FN₆O₄ 
• 1401342-11-7 C₂₀H₂₁FN₆O₃*ClH 
• 1401342-12-8 C₂₂H₂₃FN₆O₅ 
• 1401342-13-9 C₂₃H₂₃FN₆O₃ 
• 1401342-14-0 C₂₂H₂₅FN₆O₃ 

Relevant articles and documents

BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.